ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1684 • ACR Convergence 2021

    Incidence of Infections in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

    Andra R Bălănescu1, Gustavo Citera2, Virginia Pascual-Ramos3, Carol A Connell4, David Gold5, All-shine Chen4, Harry Shi6, Andrea B Shapiro7, Janet Pope8 and Hendrik Schulze-Koops9, 1“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, Collegeville, PA, 7Pfizer Inc, Peapack, NJ, 8University of Western Ontario, London, ON, Canada, 9Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany

    Background/Purpose: Previous clinical trial and real-world data suggest that risk of serious infection events (SIEs) and opportunistic infections (OIs) is similar with tofacitinib 5 mg…
  • Abstract Number: 1682 • ACR Convergence 2021

    Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

    Johanna Sigaux1, Sylvain Mathieu2, Yann N guyen3, Pauline Sanchez4, Jean-Guillaume LETAROUILLY5, Martin Soubrier2, sebastien czernichow6, Rene-Marc FLIPO7, Jeremie Sellam8 and Claire Daïen4, 1Department of Rheumatology, Hôpital Avicenne, APHP, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France, 2Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, 3Department of Internal Medicine, Hôpital Beaujon, APHP nord, Université de Paris, F-92100 Clichy, France, Paris, France, 4Department of Rheumatology, CHU de Montpellier, & University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier FRANCE University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France, 5Rheumatology Department, University Hospital of Lille, Lille, France, 6Department of Nutrition, Specialized Obesity Center, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France, 7Rheumatology Department, Lille University Hospital, Lille, France, 8INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France

    Background/Purpose: This systematic literature review and meta-analysis aimed to better estimate the effect of oral supplementation with polyunsaturated fatty acid (PUFA; omega (n)-3 and n-6)…
  • Abstract Number: 1664 • ACR Convergence 2021

    Changes in Physical Function Were Not Associated with Clinically Important Changes in Muscle Strength or Physical Performance over Time – A Cohort Study

    Rafaela Espírito Santo1, Joshua Baker2, Jordana Silva3, Lidiane Filippin4, Juliana Portes1, Claiton Brenol1, Rafael Chakr5 and Ricardo Xavier6, 1Hospital de Clínicas de Porto Alegre, Laboratório de Doenças Autoimunes, Serviço de Reumatologia, Porto Alegre, Brazil; Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, Brazil, 2University of Pennsylvania, Philadelphia, PA, 3Institute of musculoskeletal medicine, University Hospital Munster, Munster, Germany, 4Universidade La Salle, Canoas, Brazil, 5Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 6Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

    Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ) is negatively associated with muscle strength by handgrip test and positively associated with physical performance by timed…
  • Abstract Number: 1671 • ACR Convergence 2021

    COVID-19 in Patients with Rheumatoid Arthritis Compared to Patients with Osteoarthritis During the Pandemic in New York City

    Jonah Levine1, Vivian Bykerk2, Lindsay Lally1, Lisa Mandl1 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York City, NY

    Background/Purpose: COVID-19 in patients with rheumatoid arthritis (RA) is poorly understood. A recent study of mostly men with RA demonstrated increased COVID-19 risk in RA…
  • Abstract Number: 1679 • ACR Convergence 2021

    Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic

    Teresandris Polanco Mora, Jennifer Santana Peralta de Heyaime, Angelo Cornelio Vasquez, Yamilet Cruz, Edral Rodriguez, Tirso Valdez Lorie, Roberto Munoz and Rafael Alba Feriz, Hospital Docente Padre Billini, Santo Domingo, Dominican Republic

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease systemic, with a prevalence 0.5 - 1% of the population, with predilection for the female sex. (1)…
  • Abstract Number: 1663 • ACR Convergence 2021

    The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia

    Khalid Almutairi1, Johannes Nossent1, David Preen1, Helen Keen2 and Charles Inderjeeth3, 1University of Western Australia, Perth, Australia, 2University of Western Australia, Daglish, Australia, 3University of Western Australia, Nedlands, Perth, Australia

    Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
  • Abstract Number: 1662 • ACR Convergence 2021

    Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection

    Benjamin Worcester1, Dorothy Wang2, Susan Morton3 and Michelle Leech4, 1Monash Health, Melbourne, Australia, 2Melbourne Health, Clayton, Australia, 3Monash Health, Clayton, Australia, 4Monash Medical Centre, Australia, Australia

    Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
  • Abstract Number: 1670 • ACR Convergence 2021

    Increased Prevalence of Gastroesophageal Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Patompong Ungprasert1, Nipith Charoenngam2, Ben Ponvilawan3, Pitchaporn Yingchoncharoen3 and Jerapas Thongpiya4, 1Cleveland Clinic, Cleveland Heights, OH, 2Mount Auburn Hospital, Boston, MA, 3Mahidol University, Bangkok, Thailand, 4Mahdiol University, Bangkok, Thailand

    Background/Purpose: Recent experimental studies have suggested that systemic inflammatory response could lead to impairment of lower esophageal function, resulting in gastroesophageal reflux disease (GERD). Epidemiologic…
  • Abstract Number: 1665 • ACR Convergence 2021

    Physical Activity Moderates Inflammatory Gene Expression in Rheumatoid Arthritis

    Sarah Patterson1, Shenghuan Sun2, Dmitry Rychkov2, Alexandra Tsitsiklis2, Paula Hayakawa Serpa2, Patricia Katz2, Charles Langelier2 and Marina Sirota2, 1University of California San Francisco, Pacifica, CA, 2University of California San Francisco, San Francisco, CA

    Background/Purpose: Prior studies show an independent association between greater physical activity and lower inflammatory markers among adults in the general population, but the impact of…
  • Abstract Number: 1672 • ACR Convergence 2021

    Many Better, Many Worse: Mean PROMIS-29 Scores Mask Significant Shifts During COVID-19 in RA

    Susan Bartlett1, Dana DiRenzo2, Michelle Jones3 and Clifton Bingham2, 1McGill University, Montréal, QC, Canada, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins Medicine, Baltimore, MD

    Background/Purpose: Rheumatic diseases (RD) are chronic conditions that require potent immunosuppressants to control systemic inflammation. Fears associated with increased vulnerability from being on immunosuppressants plus…
  • Abstract Number: 1685 • ACR Convergence 2021

    Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – Placebo and Active Controlled Study

    Eugen Feist1, Saeed Fatenejad2, Sergey Grishin3, Elena Korneva3, Evgeniy Nasonov4, Anna Rowińska-Osuch5, Mikhail Samsonov6 and Roy Fleischmann7, 1Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 2SFC Medica, LLC, Charlotte, NC, 3R-Pharm, Moscow, Russia, 4V.A. Nasonova Reseach Institute of Rheumatology, Moscow, Russia, 5MCM Polimedica, Warsaw, Poland, 6RPharm, Moscow, Russia, 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Olokizumab (OKZ) is a humanized monoclonal antibody targeting IL-6 [1]. Here we present the results of a global phase III, head-to-head, randomized placebo (PBO)…
  • Abstract Number: 1680 • ACR Convergence 2021

    Impact of Race on the Efficacy and Safety of Tofacitinib in Patients with RA: A Post Hoc Analysis of Phase 2, 3, and 3b/4 Clinical Trials

    Grace Wright1, Eduardo Mysler2, Yi-Hsing Chen3, Cassandra Kinch4, Arne Yndestad5, Kenneth Kwok6, Mary Jane Cadatal7, Rebecca Germino8 and Alexis Ogdie9, 1Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, 2Organización Médica de Investigación, Buenos Aires, Argentina, 3Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 4Pfizer Canada ULC, Kirkland, QC, Canada, 5Pfizer Inc, Oslo, Norway, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Manila, Philippines, 8Pfizer Inc, Groton, CT, 9Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: While racial disparities in clinical outcomes for RA patients (pts) receiving bDMARDs or csDMARDs have been described,1 there remains a paucity of data on…
  • Abstract Number: 1689 • ACR Convergence 2021

    Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody

    Manoj Samant1, Alistair Wheeler2, Guang-Liang Jiang1, Moses Njenga1, Madeline Spiers1, Arian Pano1 and John F Paolini1, 1Kiniksa Pharmaceuticals Corp., Lexington, MA, 2Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda

    Background/Purpose: T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD)40/CD40L pathway. CD40 is expressed on the surface of B-cells, dendritic cells,…
  • Abstract Number: 1683 • ACR Convergence 2021

    Abatacept in Usual and in Non-Specific Interstitial Pneumonia Associated to Rheumatoid Arthritis. National Multicenter Study of 190 Patients

    Belén Atienza-Mateo1, Carlos Fernández-Díaz2, Santos Castañeda3, Rafael Melero4, Francisco Ortiz-Sanjuán5, Ivette Casafont6, Sebastián C. Rodríguez-García7, Iván Ferraz-Amaro8, Miguel Ángel gonzalez-Gay9 and Ricardo Blanco10, 1Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Reina Sofía, Murcia, Spain, 3Hospital Universitario de la Princesa, Madrid, Spain, 4Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 5Hospital Universitario La Fe, Valencia, Spain, 6Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, 7Hospital Universitario Clinic, Barcelona, Spain, 8Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 9Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 10Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe complication of Rheumatoid Arthritis (RA). Usual interstitial pneumonia (UIP) is considered to be more frequent and severe…
  • Abstract Number: 1690 • ACR Convergence 2021

    Safety and Efficacy of Long-term Sarilumab Treatment in Patients with Active Rheumatoid Arthritis: EXTEND and MONARCH Open Label Extension Studies

    Gerd Burmester1, Vibeke Strand2, Alan Kivitz3, Chih-Chi Hu4, Sheldon Wang4, Hubert van Hoogstraten5, Ray Tao6 and Roy Fleischmann7, 1Charité University Medicine Berlin, Berlin, Germany, 2Stanford University School of Medicine, Portola Valley, CA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Sanofi Genzyme, Bridgewater, NJ, 5Sanofi, Bridgewater, NJ, 6Sanofi China R&D, Shanghai, China (People's Republic), 7Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: In patients who experience intolerance or fail to respond to methotrexate, IL-6 receptor inhibitors (e.g. sarilumab) are one of the recommended options. The aim…
  • « Previous Page
  • 1
  • …
  • 540
  • 541
  • 542
  • 543
  • 544
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology